HANSOH PHARMA (03692): Almonertinib Marketing Authorization Receives Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use
HANSOH PHARMA (03692) announced that on November 12, 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for almonertinib for the treatment of non-small cell lung cancer.
HANSOH PHARMA (03692) announced that on November 12, 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for almonertinib for the treatment of non-small cell lung cancer.
Related Articles

GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.
GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.






